 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from electronic originals 
(may include minor formatting diffe rences from printed original) 
 
 
Printed on recycled paper   
127th MAINE LEGISLATURE  
 
FIRST REGULAR SESSION -2015  
 
Legislative Document  No. 180  
H.P. 138  House of Representatives, January 27, 2015  
 
 
An Act To Allow Terminally Ill Patients To Choose To Use 
Experimental Treatments  
 
 
 
 
Reference to the Committee on Health and Human Services suggested and ordered printed.  
 
 
  
 ROBERT B. HUNT  
 Clerk  
 
Presented by Representative LONGSTAFF of Waterville.  
Cosponsored by Representative WARD of Dedham, Senator BRAKEY of Androscoggin and  
Representatives: DUNPHY of Old Town, ESPLING of New Gloucester, FOWLE of 
Vassalboro, NADEAU of Winslow, PICCHIOTTI of Fairfield, SAUCIER of Presque Isle, 
SCHNECK of Bangor, Senator: PATRICK of Oxford.  
 
 

 
 Page 1 - 127LR0057(01) -1 
 Be it enacted by the People of the State of Maine as follows:  1 
Sec. 1.  22 MRSA c. 602 -A is enacted to read:  2 
CHAPTER 602 -A 3 
ACCESS TO INVESTIGAT IONAL TREATMENTS FOR  TERMINALLY ILL 4 
PATIENTS  5 
§2671.  Definitions  6 
As used in this chapter, unless the context other wise indicates, the following terms 7 
have the following meanings.  8 
1.  Carrier.  "Carrier" has the same meaning as in Title 24 -A, section 4301 -A, 9 
subsection 3.  10 
2.  Eligible patient.  "Eligible patient" means a person who has:  11 
A.  Received a diagnosis of a te rminal illness for which no standard treatment is 12 
effective and the diagnosis has been attested by the person's treating physician;  13 
B.  Considered all treatment options approved by the United States Food and Drug 14 
Administration;  15 
C.  Been unable to particip ate in a clinical trial for treatment of the terminal illness 16 
within 100 miles of the person's home address or has not been accepted into a clinical 17 
trial within one week of completion of the clinical trial application process;  18 
D.  Received a recommendatio n from the person's treating physician for an 19 
investigational drug, biological product or device;  20 
E.  Given written, informed consent for the use of the investigational drug, biological 21 
product or device under paragraph D or, if the person is a minor or la cks the mental 22 
capacity to provide informed consent, whose parent or legal guardian has given 23 
written, informed consent on the person's behalf; and  24 
F.  Received documentation from the person's treating physician that the person 25 
meets all of the conditions in this subsection.  26 
3.  Investigational drug, biological product or device.  "Investigational drug, 27 
biological product or device" means a drug, biological product or device that has 28 
successfully completed Phase I of a United States Food and Drug Administra tion- 29 
approved clinical trial but has not yet been approved for general use by the United States 30 
Food and Drug Administration and remains under investigation in such a clinical trial.  31 
4.  Terminal illness.  "Terminal illness" means a disease or condition th at, without 32 
life-sustaining measures, is reasonably expected to result in death within 6 months.  33 
5.  Treating physician.  "Treating physician" means a physician who has primary 34 
responsibility for the care of a patient and treatment of that patient's termin al illness.  35 
 
 Page 2 - 127LR0057(01) -1 
 6.  Written, informed consent.  "Written, informed consent" means a written 1 
document signed by a patient or, if the patient is a minor or lacks the mental capacity to 2 
provide informed consent, a parent or legal guardian of the patient.  The doc ument must 3 
be attested by the patient's treating physician and a witness and include the following 4 
information:  5 
A.  An explanation of the United States Food and Drug Administration -approved 6 
treatments for the disease or condition from which the patient suf fers; 7 
B.  A statement that the patient concurs with the patient's treating physician that all 8 
United States Food and Drug Administration -approved and standard treatments for 9 
the disease or condition from which the patient suffers are unlikely to prolong th e 10 
patient's life;  11 
C.  Clear identification of the specific investigational drug, biological product or 12 
device that the patient is seeking to use;  13 
D.  A description of the best and worst potential outcomes of using the investigational 14 
drug, biological produ ct or device identified under paragraph C with a description of 15 
the most likely outcome.  The description must include the possibility that new, 16 
unanticipated, different or worse symptoms might result and that death could be 17 
hastened by the proposed treatm ent.  The description must be based on the treating 18 
physician's knowledge of the proposed treatment in conjunction with the treating 19 
physician's knowledge of the patient's overall medical condition;  20 
E.  A statement that the patient's carrier is not obligat ed to pay for any care or 21 
treatments consequent to the use of the investigational drug, biological product or 22 
device identified under paragraph C, unless the carrier is specifically required to do 23 
so by law or contract;  24 
F.  A statement that the patient's e ligibility for hospice services may be withdrawn if 25 
the patient begins curative treatment with the investigational drug, biological product 26 
or device identified under paragraph C and that hospice services may be reinstated if 27 
the curative treatment ends an d the patient meets hospice eligibility requirements;  28 
G.  A statement that the patient may not be eligible for in -home health care services if 29 
treatment with the investigational drug, biological product or device identified under 30 
paragraph C begins; and  31 
H.  A statement that the patient understands that the patient is liable for all expenses 32 
consequent to the use of the investigational drug, biological product or device 33 
identified under paragraph C and that the liability extends to the patient's estate, 34 
unless a contract between the patient and the manufacturer of the investigational 35 
drug, biological product or device states otherwise.  36 
§2672.  Availability of investigational drug, biological product or device by 37 
manufacturer  38 
A manufacturer of an investigation al drug, biological product or device may make 39 
available the investigational drug, biological product or device to an eligible patient.  40 
 
 Page 3 - 127LR0057(01) -1 
 1.  Compensation.  A manufacturer may provide an investigational drug, biological 1 
product or device to an eligible patie nt with or without receiving compensation.  2 
2.  Costs.  A manufacturer may require an eligible patient to pay the costs of or 3 
associated with the manufacture of an investigational drug, biological product or device.  4 
§2673.  Insurance  5 
This chapter does not e xpand the coverage required of a carrier under the Maine 6 
Insurance Code.  7 
1.  Coverage.  A carrier may provide coverage for an investigational drug, biological 8 
product or device.  9 
2.  Coverage denial.  Unless specifically required to provide coverage by law or 10 
contract, a carrier may deny coverage to an eligible patient from the time the eligible 11 
patient begins use of an investigational drug, biological product or device through a 12 
period not to exceed 6 months from the time the investigational drug, biologica l product 13 
or device is no longer used by the eligible patient.  A carrier may not deny coverage for a 14 
preexisting condition or coverage for benefits that commenced prior to the time the 15 
eligible patient began use of the investigational drug, biological pro duct or device.  16 
§2674.  Action against health care practitioner license prohibited  17 
A licensing board may not revoke, refuse to renew or suspend the license of or take 18 
any action against a health care practitioner as defined in Title 24, section 2502, 19 
subse ction 1 -A based solely on the health care practitioner's recommendations to an 20 
eligible patient regarding access to or treatment with an investigational drug, biological 21 
product or device, as long as the recommendations are consistent with medical standard s 22 
of care.  23 
§2675.  Officials, employees and agents of the State  24 
1.  Violation.  An official, employee or agent of the State may not block or attempt to 25 
block an eligible patient's access to an investigational drug, biological product or device.  26 
2.  Penalty .  An official, employee or agent of the State who violates this section 27 
commits a Class E crime.  28 
3.  Medical standards of care.  This section does not prohibit an official, employee 29 
or agent of the State from providing counseling, advice or a recommendati on consistent 30 
with medical standards of care.  31 
§2676.  No cause of action created  32 
This chapter does not create a private cause of action against a manufacturer of an 33 
investigational drug, biological product or device or against any other person or entity 34 
involved in the care of an eligible patient using the investigational drug, biological 35 
product or device for any harm done to the eligible patient resulting from the 36 
investigational drug, biological product or device if the manufacturer or other person or 37 
 
 Page 4 - 127LR0057(01) -1 
 entity is complying in good faith with the provisions of this chapter and has exercised 1 
reasonable care.  2 
§2677.  Clinical trial coverage  3 
This chapter does not affect the mandatory health care coverage for participation in 4 
clinical trials pursuant to Title 24 -A, section 4310.  5 
SUMMARY  6 
This bill authorizes manufacturers of drugs, biological products and devices that have 7 
completed Phase I of a United States Food and Drug Administration -approved clinical 8 
trial but have not yet been approved for general use and re main under clinical 9 
investigation to make them available to eligible terminally ill patients.  The bill does not 10 
require health insurers to provide coverage for the cost of such a drug, biological product 11 
or device but authorizes insurers to provide such c overage.  The bill prohibits licensing 12 
boards from revoking, refusing to renew or suspending the license of or taking any other 13 
action against a health care practitioner based solely on the practitioner's recommendation 14 
to an eligible patient regarding acc ess to or treatment with such a drug, biological product 15 
or device.  It prohibits any official, employee or agent of the State from blocking or 16 
attempting to block access by an eligible patient to such a drug, biological product or 17 
device.  18 
 
